Surgery for Obesity and Related Diseases
Volume 4, Issue 3 , Pages 423-429, May 2008

Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese

Presented at Annual Meeting of the American Society for Bariatric Surgeons, June 11 to June 16, 2007, San Diego, California

  • Anthony Brancatisano, B.Appl.Sc., M.B.B.S., Ph.D.

      Affiliations

    • Institute of Weight Control, Sydney, Australia
    • Corresponding Author InformationReprint requests: Dr Anthony Brancatisano, Institute of Weight Control, 495 Windsor Road, Baulkham Hills, Sydney, NSW 2153, Australia.
    • ,
  • Sara Wahlroos, B.Med.Sc.

      Affiliations

    • Institute of Weight Control, Sydney, Australia
    • ,
  • Slade Matthews, B.Med.Sc., Dip.Ed., Ph.D.

      Affiliations

    • Bosch Institute of Medical Research, University of Sydney, Sydney, Australia
    • ,
  • Roy Brancatisano, M.B.B.S.

      Affiliations

    • Institute of Weight Control, Sydney, Australia

Received 14 May 2007; received in revised form 22 July 2007; accepted 24 October 2007. published online 29 January 2008.

Abstract 

Background

To assess the efficacy of the Swedish adjustable gastric band in the treatment of type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), and the metabolic syndrome (MS) in the morbidly obese.

Methods

We identified all patients with T2DM, IGT, or the MS at surgery from our database of 905 consecutive patients who had undergone placement of the Swedish adjustable gastric band between January 2001 and April 2007. The patients were followed up by our multidisciplinary team, and their T2DM was managed by their treating primary care physician and/or endocrinologist.

Results

A total of 682 patients had >6 months of follow-up. Of these, 78 patients had T2DM, 64 had IGT, and 100 had the MS. At a median follow-up of 12.5 months, patients with T2DM had a mean ± SD excess weight loss of 38% ± 15%. This was associated with hemoglobin A1c and fasting blood sugar levels decreasing from 8.0% ± 1.7% to 6.1% ± 1.0% (P <.0001) and from 9.6 ± 3.4 mmol/L to 5.7 ± 1.5 mmol/L (P <.0001), respectively. Remission and/or improvement in patients with T2DM was judged by the complete cessation and/or reduction in medication and normalization of laboratory values. This occurred in 81% of those taking oral hypoglycemic agents. Of the patients taking a combination of oral hypoglycemic agents and insulin, 43% ceased and/or reduced their oral hypoglycemic agents, and 93% ceased and/or reduced their insulin requirements. Of those on insulin only, 75% ceased and/or reduced their insulin. No patient with IGT developed diabetes or progressed to require medications. Remission and/or improvement in the MS occurred in 88% of patients. Remission of T2DM was dependent on both the magnitude of excess weight loss (P = .008) and the duration of the pre-existing T2DM. Using binary logistic regression analysis, a duration of T2DM of <5 years before surgery was 6.5 times more likely to lead to resolution of T2DM after the weight loss (P = .004).

Conclusion

Weight loss after Swedish adjustable gastric band placement is an effective treatment of T2DM in morbidly obese patients, with early intervention offering the greatest chance of remission. It might even prevent the occurrence of T2DM in patients with IGT.

Keywords: Swedish adjustable gastric band, Bariatric surgery, Diabetes, Impaired glucose tolerance, Metabolic syndrome, Morbid obesity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was supported by a grant from Johnson & Johnson Medical, the manufacturer of the Swedish adjustable gastric band.

PII: S1550-7289(07)00708-3

doi:10.1016/j.soard.2007.10.011

Surgery for Obesity and Related Diseases
Volume 4, Issue 3 , Pages 423-429, May 2008

Article Tools